Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborator: Collins Medical Trust
• Treatments: Thioctic Acid

Criteria

Inclusion Criteria:

• diagnosis of CIDP

• on a stable dose of immunotherapy for at least 3 months before enrolling in the study

Exclusion Criteria:

• myelopathy or evidence of central demyelination

• persistent neurological deficits from stroke, CNS trauma, or peripheral neuropathy from other causes (eg, diabetes mellitus, IgM, paraproteinaemia, or uraemic, toxic, or familial neuropathy)

• evidence of systemic disease that might cause neuropathy

• heart diseases (congestive heart failure or arrhythmia)

• pulmonary conditions (asthma or CIPD)

• rheumatoid conditions (such as rheumatoid arthritis)

• renal failure